Inactive Instrument

POIT BIOP

Equities

RACA

US7305411099

This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from S&P Biotechnology Select Industry Index CI
POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from S&P Global BMI Index CI
POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from S&P TMI Index CI
Fusion Pharmaceuticals an 'Attractive' Takeover Target Following Recent Radiopharma Deals, Oppenheimer Says MT
Fusion Pharmaceuticals 'Last Available Target' With Solid Supply Chain After Point Biopharma, RayzeBio Takeovers, Oppenheimer Says MT
Eli Lilly: successful takeover bid for POINT Biopharma Global CF
Eli Lilly Completes Acquisition of Point Biopharma Global MT
Eli Lilly Completes Acquisition of POINT Biopharma Global MT
Swiss Shares Decline Amid Lingering Concerns for Growth of Local Economy MT
Eli Lilly Closes $1.4 Billion Takeover of Point Biopharma MT
POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from NASDAQ Composite Index CI
Eli Lilly and Company completed the acquisition of POINT Biopharma Global Inc. from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others. CI
North American Morning Briefing : Dow Futures Fall -2- DJ
Brookline Capital Downgrades POINT Biopharma Global to Hold From Buy, Cuts Price Target to $12.50 From $27 MT
Lantheus, POINT Biopharma Say Trial of 177Lu-PNT2002 for Metastatic Castration-Resistant Prostate Cancer Meets Endpoint MT
Eli Lilly Extends Tender Offer for POINT Biopharma Acquisition to Dec. 22 MT
Eli Lilly: further extension of takeover bid for Point Biopharma Global CF
Lantheus Holdings, Inc. and POINT Biopharma Global Inc. Announce Positive Topline Results from Pivotal Splash Trial in Metastatic Castration-Resistant Prostate Cancer CI
Eli Lilly Further Extends Tender Offer Deadline for Point Biopharma Shares MT
Eli Lilly: further extension of its tender offer for POINT Biopharma CF
Eli Lilly Extends Tender Offer for POINT Biopharma to Dec. 15 MT
Eli Lilly Extends Tender Offer Period for Point Biopharma Global Acquisition MT
Eli Lilly extends tender offer to buy Point Biopharma RE
Eli Lilly: has extended its tender offer for Point Biopharma CF
Eli Lilly Extends Tender Offer for POINT Biopharma Acquisition MT
Chart POIT BIOP
More charts
POINT Biopharma Global Inc. is a radiopharmaceutical company. The Company is engaged in building a platform for the clinical development and commercialization of radioligands that fight cancer. The Company is focused on transforming precision medicine by combining a portfolio of radiopharmaceutical assets, a seasoned management team, a pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like actinium-225 (Ac) and lutetium-177 (Lu). Its pipeline consists of late-stage programs in prostate cancer (PNT2002) and neuroendocrine tumors (PNT2003). Its Lu-PNT2002 is a late-stage prostate-specific membrane antigen (PSMA) targeted radioligand therapy. Its Lu-PNT2003 is a late-stage somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors. Its PNT2004 is a fibroblast activation protein-a (FAP) targeting program being developed for use in multiple tumor types.
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock POIT BIOP - Nasdaq
  4. News POIT BIOP
  5. Eli Lilly Extends Tender Offer Period for Point Biopharma Global Acquisition
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer